Not sure they had any choice - once they had the results they needed to do initial analysis and inform the market (and prevent any insider trading, though that didn't seem to work).
Anyway, the announcement is for top-line results, with further analysis to come. As has been pointed out, it may well be that further analysis shows the legacy effect distorted the results - making them appear to be less statistically significant than they actually were.
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-236
-
- There are more pages in this discussion • 392 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $269.6M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 50.5¢ | 46.0¢ | $2.255M | 4.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 21052 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |